scholarly journals Long-Term Anatomical and Functional Outcome of Three Intravitreal Bevacizumab Injections for Persistent Macular Edema after Idiopathic Macular Epiretinal Membrane Peeling

2014 ◽  
Vol 1 (1) ◽  
pp. 1-8 ◽  
Author(s):  
Yo-Chen Chang ◽  
Chia-Ching Lin ◽  
Wen-Chuan Wu
Keyword(s):  
Macular Edema ◽  
Functional Outcome ◽  
Epiretinal Membrane ◽  
Intravitreal Bevacizumab ◽  
Membrane Peeling

LONG-TERM EFFECT OF INTRAVITREAL BEVACIZUMAB (AVASTIN) IN PATIENTS WITH CHRONIC DIFFUSE DIABETIC MACULAR EDEMA

Retina ◽  
2008 ◽  
Vol 28 (8) ◽  
pp. 1053-1060 ◽  
Author(s):  
DANIEL KOOK ◽  
ATMIN WOLF ◽  
THOMAS KREUTZER ◽  
ALJOSCHA NEUBAUER ◽  
RUPERT STRAUSS ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Intravitreal Bevacizumab ◽  
Term Effect ◽  
Long Term Effect ◽  
Diffuse Diabetic Macular Edema

scholarly journals Short term effect of intravitreal bevacizumab for diabetic macular edema associated with epiretinal membrane

2018 ◽  
Vol 62 (3) ◽  
pp. 212-216 ◽  
Author(s):  
Ashraf Khorasani Maryam ◽  
Mohammadi Tafgeh ◽  
Motallebi Mahmoud ◽  
Anvari Pasha ◽  
Sedaghat Ahad ◽  
...  
Keyword(s):  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Epiretinal Membrane ◽  
Intravitreal Bevacizumab ◽  
Term Effect ◽  
Short Term ◽  
Short Term Effect

scholarly journals Factors associated with 1-year visual response following intravitreal bevacizumab treatment for diabetic macular edema: a retrospective single center study

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Janejit Choovuthayakorn ◽  
Apichat Tantraworasin ◽  
Phichayut Phinyo ◽  
Jayanton Patumanond ◽  
Paradee Kunavisarut ◽  
...  
Keyword(s):  
Visual Impairment ◽  
Macular Edema ◽  
Diabetic Macular Edema ◽  
Intravitreal Bevacizumab ◽  
Individual Treatment ◽  
Visual Response ◽  
Visual Responses ◽  
Visual Gain ◽  
Long Term Treatment

Abstract Background To explore the association of clinical characteristics and retinal microstructural features on optical coherence tomography in predicting 1-year visual response following intravitreal bevacizumab injections in eyes with visual impairment from center-involved diabetic macular edema (CI-DME). Methods Medical records of patients with visual impairment from CI-DME, who initiated intravitreal bevacizumab injections between Jan 2012 and Dec 2016 and were followed for a minimum of 12 months were retrospectively reviewed. Results The study included 226 eyes with a mean (SD) baseline visual acuity (VA) of 51.8 (19.1) letters. At week 12, following the three initial treatments, a mean (SD) VA improved to 61.7 (17.8) letters. Visual gain ≥ 10 letters was observed in 109 eyes (48.2%), while a limited early visual gain < 5 letters was noted in 80 eyes (35.4%). At one year, 110 eyes (48.7%) achieved a good VA gain ≥ 10 letters. In addition, eyes with poor baseline VA had a higher proportion of eyes that obtained limited early VA gained at week 12 (< 5 letters) and maintained in this visual response category at moth 12 compared to eyes with better baseline VA (74.1% versus 59.1%). In the multivariable logistic regression, the following factors reduced the probability of 1-year visual gain ≥ 10 letters: elderly (p = 0.040), better baseline vision (p = 0.001), and limited early visual gain < 5 letters at week 12 (p < 0.001). In multivariable linear regression, male (p = 0.010) and eyes with the presence of hyperreflective foci on baseline OCT (p = 0.010) were likely to have higher VA improvement. However, eyes with better baseline VA (p = 0.002), limited early VA gain at week 12 (p < 0.001), and a presence of EZ disruption at week 12 (p = 0.002) were likely to have less VA improvement. Conclusions Although bevacizumab is considered as effective management for CI-DME, variability in treatment responses is expected. This study revealed that baseline characteristics and visual responses at week 12 might help predict the long-term treatment response. Eyes with characteristics at risk of limited long-term visual outcome may require attention in optimizing their individual treatment strategies.

Sign in / Sign up

Export Citation Format

Share Document